Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Press

Showing results (101-110 of 272) with videos related to

Pageof 28
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 8, 2004
High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumesJoseph G Rajendran, Darrell R Fisher, Ajay K Gopal, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 22, 2000
Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cellsP A Carpenter, S Pavlovic, J Y Tso, et al.
Blood|February 1, 1987
Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomasO W Press, F Appelbaum, J A Ledbetter, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 17, 2011
Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remissionFranz Buchegger, Cristian Antonescu, Claudine Helg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2013
Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies?F Buchegger, J-P Mach, O W Press, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246O W Press, M LeBlanc, T J O'Rourke, et al.
ACS Applied Materials & Interfaces|March 10, 2015
Temozolomide nanoparticles for targeted glioblastoma therapyChen Fang, Kui Wang, Zachary R Stephen, et al.
Bone Marrow Transplantation|April 25, 2006
A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantationK Lilleby, P Garcia, T Gooley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911Oliver W Press, Joseph M Unger, Rita M Braziel, et al.
Bioconjugate Chemistry|January 20, 2005
Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphomaKevin J Hamblett, Oliver W Press, Damon L Meyer, et al.
Pageof 28

Showing results (101-110 of 272) with videos related to

Sort By:
Pageof 28
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 8, 2004
High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumesJoseph G Rajendran, Darrell R Fisher, Ajay K Gopal, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 22, 2000
Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cellsP A Carpenter, S Pavlovic, J Y Tso, et al.
Blood|February 1, 1987
Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomasO W Press, F Appelbaum, J A Ledbetter, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 17, 2011
Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remissionFranz Buchegger, Cristian Antonescu, Claudine Helg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2013
Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies?F Buchegger, J-P Mach, O W Press, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246O W Press, M LeBlanc, T J O'Rourke, et al.
ACS Applied Materials & Interfaces|March 10, 2015
Temozolomide nanoparticles for targeted glioblastoma therapyChen Fang, Kui Wang, Zachary R Stephen, et al.
Bone Marrow Transplantation|April 25, 2006
A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantationK Lilleby, P Garcia, T Gooley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911Oliver W Press, Joseph M Unger, Rita M Braziel, et al.
Bioconjugate Chemistry|January 20, 2005
Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphomaKevin J Hamblett, Oliver W Press, Damon L Meyer, et al.
Pageof 28